The AHA, ACC, and SCAI have released focused updates to existing STEMI and PCI guidelines. New to the guidelines are recommendations regarding prasugrel, left main stenting, and DES vs BMS for primary PCI, among others.
Here are some of the highlights:
Community system for MI treatment— Each community is encouraged to develop an organized system to treat MIs, modeled after the AHA’s Mission: Lifeline initiative and the ACC’s Door-to-Balloon (D2B) campaign, including protocols to identify MI patients before they reach the hospital, sending patients to PCI-capable hospitals, and transferring patients who arrive at non-PCI hospitals to PCI hospitals when feasible.
PCI Hospitals— For patients who can not be treated initially at a PCI hospital, thrombolysis should be initiated, followed by transfer afterwards for high risk patients to a PCI hospital.
Left Main Coronary Artery Stenting— Stenting for the LMCA is now accepted in patients in lower risk patients who may be at increased risk with surgery. “There is mounting evidence that stenting of the left main coronary artery, under certain circumstances, does carry a reasonably good outcome,” said Spencer B. King, III, a co-chair of the writing group, in a press release. “Now stenting might be considered, based on the specific anatomy of the coronary arteries and the risk profile of the patient.”
Fractional flow reserve– FFR can help interventionalists decide which intermediate lesions can benefit from a stent, but its routine use is not recommended.
Aspiration thrombectomy should be considered for MI patients undergoing PCI.
IIb/IIIa inhibitors– Abciximab, tirofiban, or eptifibatide may be considered for primary PCI. The use of IIb/IIIa inhibitors prior to arrival in the cath lab is uncertain.
Bivalirudin may be an alternative anticoaulant in primary PCI, especially in patients who are at high bleeding risk.
An insulin-based regimen may be used in STEMI patients to achieve and maintain glucose levels below 180 mg/dl.
Drug-eluting stents may be used as an alternative to bare-metal stents for primary PCI, but it is imperative to consider problems that may be caused by prolonged thienopyridine therapy.
An isosmolar contrast medium (Iodixanol) or a low-molecular-weight contrast medium other than ioxaglate or iohexol should be used during angiography in patinets with chronic kidney disease.
Here is the press release from the ACC:
Updated Guidelines Include Latest Findings on Treatment of Heart Attack, Coronary Disease
Team of experts tackles double update in record time
A collaborative, fast-track update to two sets of clinical guidelines calls for community-wide coordination of emergency services so that heart attack patients receive the most effective treatment as quickly as possible. The new document also lays out several new treatment options, not only for patients who are experiencing a heart attack but also for those who undergo angioplasty and stenting to open clogged coronary arteries.
The new guidelines update is a joint effort of the American College of Cardiology (ACC), the American Heart Association (AHA), and the Society for Cardiovascular Angiography and Interventions (SCAI). It simultaneously brings focused updates to two separate clinical guidelines, one on the management of patients with ST-elevation myocardial infarction (STEMI) — a major heart attack — and the other on percutaneous coronary intervention (PCI)—a set of procedures in which a tiny balloon is inflated in a narrowed coronary artery to widen the blockage (it often includes inserting a small metal tube, or stent, into the artery to better maintain blood flow).
The fast-track document will help healthcare providers interpret the latest clinical research on two important and inter-related areas of cardiology, and quickly put this new knowledge into clinical practice.
“The focused update is a way of responding quickly to new information that will benefit patients,” said Sidney C. Smith, Jr., M.D., a professor of medicine and director of the Center for Cardiovascular Science and Medicine at the University of North Carolina at Chapel Hill and chair of the writing group. “We were able to look over a year of major studies and incorporate the most valuable findings into the existing guidelines.”
One of the most important new recommendations is for each community to develop an organized system of emergency care for patients who are having a heart attack, modeled after the AHA’s Mission: Lifeline initiative and the ACC’s Door-to-Balloon (D2B) campaign. This plan would include protocols for identifying heart attack patients even before they reach the hospital and directing ambulances to medical centers capable of rapidly performing PCI to open the blocked coronary artery. The plan would also include protocols for managing heart attack patients who initially arrive at hospitals not equipped to perform PCI, including arrangements for rapid transfer to a PCI center, whenever possible.
In addition, the guidelines address the management of patients who initially go to a non-PCI hospital and cannot be transferred quickly. These patients should be treated with clot-busting drugs, according to the guidelines. Afterward, if patients are judged to be high-risk, it is reasonable to transfer them to a PCI center without delay, rather than waiting to observe whether the clot-busters are successful, as is common practice today.
Over the last few years, communities around the country have begun to put in place organized systems of heart attack care, but they are not yet widespread. Community members can play an important part in getting the ball rolling, said Frederick G. Kushner, M.D., medical director of The Heart Clinic of Louisiana and a clinical professor of medicine at Tulane School of Medicine in New Orleans and co-chair of the writing group.
“Patients should become advocates and urge their local hospital to become part of a community network that follows the recommendations of the Mission: Lifeline program,” he said. “It’s the best way to quickly activate the chain of events that are critical to opening a blocked artery causing a heart attack.”
Another major change in the guidelines is greater acceptance of stenting for the treatment of the left main coronary artery. The left main is one of the two coronary arteries that come directly off of the aorta, before it splits into smaller branches. Because a complete blockage of the left main coronary artery would cut off the blood supply to the majority of the heart, bypass surgery has long been the recommended treatment for patients with a narrowing in this artery. Recent studies, however, have shown that in certain patients, stenting of the left main is safe and effective. As a result, the new guidelines now allow for left main stenting as an option when procedural complications are likely to be low and the patient faces an increased risk if treated surgically.
“There is mounting evidence that stenting of the left main coronary artery, under certain circumstances, does carry a reasonably good outcome,” said Spencer B. King, III, M.D., president of the Saint Joseph’s Heart and Vascular Institute and a professor of medicine emeritus at Emory University School of Medicine in Atlanta and co-chair of the writing group. “Now stenting might be considered, based on the specific anatomy of the coronary arteries and the risk profile of the patient.”
The guidelines update incorporates several additional changes, including the following:
- Use of a pressure wire threaded into the coronary artery to gauge whether plaque build-up in a particular area is actually interfering with blood flow. This assessment of “fractional flow reserve” helps interventional cardiologists pinpoint which coronary obstructions need to be widened with a stent and which do not.
- Use of aspiration thrombectomy, a technique in which the clot causing a heart attack is sucked out through a catheter before a stent is placed.
- Use of the new anti-clotting medication prasugrel, an alternative to clopidogrel for patients treated with PCI.
- Recommendations for use of a variety of blood thinners and anti-clotting medications before, during or after PCI.
- Broader recommendations on the types of x-ray dye that may be safely used to view the coronary arteries during PCI in patients with chronic kidney disease.
“People have heard a lot about evidence-based medicine,” said Dr. King. “These guidelines are a distillation of all the relevant evidence. They will help physicians to make the best choices for their patients.”
“The new process of rapidly updating guidelines will allow practioners the opportunity to utilize contemporary evidence-based medicine to make critical decisions. Our patients will have more treatment options because the new guidelines include provisions for stenting left main and complex three-vessel coronary artery disease and stress the use of physiologic lesion assessment to optimize clinical outcomes,” said Steven R. Bailey, M.D., FACC, FSCAI, chief of the Dolph and Janey Briscoe Division of Cardiology at University of Texas Health Sciences Center at San Antonio, SCAI president, and a representative of SCAI on the writing committee.
Dr. Smith was chair of both the PCI Writing Group and the ACC/AHA Task Force on Practice Guidelines. Dr. Kushner was co-chair of the STEMI Writing Group and Dr. King was co-chair of the PCI Writing Group.
The new focused guidelines update will be published in the December 1, 2009, issue of Journal of the American College of Cardiology, the December 1, 2009 issue ofCirculation: Journal of the American Heart Association, and online November 18, 2009, in Catheterization and Cardiovascular Interventions. It is also available on the Web sites of the American College of Cardiology (www.acc.org), the American Heart Association (my.americanheart.org), and the Society for Cardiovascular Angiography and Interventions (www.scai.org).